UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 8-KCURRENTREPORTPursuant to Section 13 or 15(d)of The Securities Exchange Act of 1934Date of Report (Date of Earliest Event Reported): January 4, 2019UNUM THERAPEUTICS INC.(Exact name of registrant as specified in its charter)Delaware0-5308248(State or other jurisdictionof incorporation)(CommissionFile Number)(I.R.S. Item 7.01Regulation FD Disclosure.Unum Therapeutics Inc. (the Company) is furnishing a corporate presentation, attached as Exhibit 99.1 to this Current Report on Form 8-K, which the Company intends to use from time to time in meetings with investors and others beginning on January 7, 2019. Exhibit 99.2 CORRECTING and REPLACING Unum Therapeutics Announces 2019 Goals and Expected MilestonesIn a release issued yesterday under the same headline by Unum Therapeutics Inc. (NASDAQ: UMRX), please note the anticipated 2019 milestone for BOXR1030 hasbeen changed from initiating clinical development to initiating preclinical development in the last paragraph.
Jun 17, 2016 Versi bawaan Virmware Bolt Orion adalah MoviMax MV1 Bolt V016 (Sudah di Unlock) sedangkan Versi terbaru Virmware Bolt Orion adalah MoviMax MV1 Bolt V022 (CDMA) jadi kalau dari Versi bawaan di upgrade ke MoviMax MV1 Bolt V022, otomatis modem tersebut sudah tidak bisa di Unlock lagi DENGAN CARA APAPUN. Baca Juga: Cara Unlock Modem Bolt Orion MoviMax MV1 4G Terbaru 2019 (100% Work) Jika muncul peringatan “Modem Not Found”, artinya driver modem belum terinstall. Untuk itu, silahkan install driver modem dengan cara: Buka Device Manager. Kemudian, cari pengaturan ZTE LTE Technologies MSM.
The corrected release follows:- Multiple Data Readouts from ATTCK-20-03 and ATTCK-17-01 Expected in 2019 - Initial Data onATTCK-34-01, Unums First Program in Solid Tumors, Expected in Second Half of 2019 -First Development Candidate from BOXR Platform Advancing Toward Clinical Development -CAMBRIDGE, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE) UnumTherapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of novel cellular immunotherapies, today announced its anticipated milestones for 2019.Unum made substantial progress in 2018 as we reported early data from our programs in non-Hodgkin lymphoma andmultiple myeloma, while simultaneously expanding applications of our ACTR platform into solid tumors and introducing a second novel technology platform, BOXR, designed to improve the functionality of engineered T cells, said Chuck Wilson, CEOof Unum. We expect 2019 also to be a year of significant momentum, with data expected from all four of our ongoing clinical programs, including readouts from theATTCK-20-03 and ATTCK-17-01 trials, as well as an initial data readout from our firststudy in solid tumors.
Additionally, we continue to innovate in the field of cell therapy and have recently nominated our first development candidate from our BOXR technology platform to advance toward clinical development.Anticipated 2019 MilestonesACTR707 + rituximab inr/r NHL Complete the dose escalation phase ofATTCK-20-03, the ongoing, multicenter Phase 1 study testing ACTR707 in combination with rituximab to treat patients with relapsed/refractory B cell non-Hodgkin lymphoma. The Company is headquartered in Cambridge, MA.Forward looking StatementsThis press release containsforward-looking statements.